Assessment of the stability of TGFβ3 bioactivity for potential bioreactor applications by Vonwil, D. et al.
Institutional Repository of the University of Basel 
University Library
Schoenbeinstrasse 18-20
CH-4056 Basel, Switzerland 
http://edoc.unibas.ch/
Year: 2008 
Assessment of the stability of TGFβ3 bioactivity for potential 
bioreactor applications 
Vonwil, D. and Wendt, D. and Stroebel, S. and Wallny, H. J. and Gygax, D. and Heberer, M. and Martin, I. 
Posted at edoc, University of Basel 
Official URL: http://edoc.unibas.ch/dok/A5248829 
Originally published as: 
Vonwil, D. and Wendt, D. and Stroebel, S. and Wallny, H. J. and Gygax, D. and Heberer, M. and Martin, I.. 
(2008) Assessment of the stability of TGFβ3 bioactivity for potential bioreactor applications. Biochemical 
engineering journal, Vol. 3. S. 586-589. 
Assessment of the stability of TGF-β3 bioactivity 
for potential bioreactor applications 
D. Vonwila, D. Wendta, S. Ströbela, H. J. Wallnyb, D. Gygaxc, M. 
Heberera, I. Martina,* 
a   Departments of Surgery and of Research, University Hospital Basel, 
Switzerland 
b Novartis Pharma AG, Biotechnology Development, Switzerland 
c University of Applied Sciences Northwestern Switzerland
*To whom correspondence should be addressed:
Ivan Martin 
Institute for Surgical Research and Management 
Hebelstrasse 20, 4031 Basel, Switzerland 
Telefone: +41 61 265 2384, fax: +41 61 265 3990, e-mail: 
imartin@uhbs.ch 
1 
Abstract 
In order to develop suitable bioreactor systems and processes for 
automated and standardized cell cultures involving the use of bioactive 
factors, we determined the stability of TGFβ3 over storage time and 
under conditions typically used for mammalian cell culture. Using a 
reporter gene assay with firefly luciferase as readout, significant 
reduction of TGFβ3 bioactivity was detected to occur both in serum 
containing (SCM) and serum free medium (SFM). The residual activity, 
quantified by parallel line assays, progressively decreased with time, 
down to 60% in SCM and 84% in SFM after one week at 37°C, with no 
further decrease until three weeks, whereas such loss could not be 
predicted using a conventional ELISA method. The reduction of TGFβ3 
bioactivity had a negligible influence in a typical biological assay (e.g., 
chondrocyte proliferation), supporting the possibility of prolonged 
storage of medium pre-supplemented with TGFβ3 for bioreactor-based 
chondrocyte expansion. With the ultimate goal of defining suitable 
operating protocols for automated cell culture bioreactors, the proposed 
approach should be extended to assessing the stability of other possibly 
labile medium supplements. 
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Introduction 
 Bioreactor systems offer a large potential to introduce automation 
and standardization in cell and tissue culture, which are key functions for 
reproducible laboratory practice and, prospectively, for effective and 
safe translation of cell-based therapies in the clinic [1]. With regard to 
automation and simplification of liquid handling, the use of culture 
medium already including the required bioactive supplements (e.g., 
growth factors, vitamins) would be technically desirable as compared to 
having the different components stored at different 
temperatures/compartments. With regard to standardization, however, 
storing a fully supplemented medium at specific conditions, ready for 
being dispensed to the culture, raises the question of whether and to 
which extent the bioactivity of its components is stable over time.  
 Transforming growth factor beta 3 (TGFβ3) is widely used as 
culture supplement as it is known to regulate proliferation, 
differentiation, migration and survival of a large variety of mammalian 
cells during in vitro culture [2]. Among other functions, TGFβ3 is an 
important modulator of the hematopoietic and immune system [3], and 
plays an important role in the chondrogenic differentiation of 
mesenchymal stem cells [4] and in the expansion and redifferentiation of 
articular chondrocytes [5, 6]. 
 In this paper, we aimed at determining the stability of TGFβ3 
over storage time, under conditions commonly used for mammalian cell 
culture. A specific and sensitive reporter gene assay using firefly 
luciferase as readout [7], which recognizes only biologically active 
molecules, was used to quantify TGFβ3 bioactivity. Results were 
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compared with measurements based on a conventional enzyme linked 
immunosorbent assay (ELISA) method, and associated to the functional 
performance of the molecule in chondrocyte cultures.  
 
Materials and Methods 
Storage conditions for TGFβ3 solutions 
Stock solutions of 10 μg/ml recombinant human TGFβ3 (R&D, 
UK), reconstituted in phosphate-buffered saline, 4mM hydrochloric acid, 
and 1mg/ml human serum albumin, were stored for up to 21 days at a 
temperature of either 25 °C or 37°C in aliquots of 1 ml in cryotubes 
(Greiner bioone, Switzerland; polypropylene). The pH remained 
constant at 8.1. Storage media consisted of Dulbecco’s Modified Eagle’s 
Medium (DMEM, Gibco, UK) with final concentrations of 10% fetal 
bovine serum (FBS, Gibco, UK), 100 U/ml penicillin + 100 µg/ml 
streptomycin + 0.29 mg/ml L-glutamine (Gibco, UK), 100 mM HEPES 
(Gibco, UK), 1 mM sodium pyruvate (Gibco, UK), 0.1 mM ascorbic 
acid 2-phosphate (Sigma Chemical, USA) and 10 µg/ml human insulin 
(Novo Nordisk, Denmark) [6] (serum containing medium, SCM), or as a 
substitute of FBS, ITS+1 (Sigma Chemical, St. Louis; i.e., 10 µg/ml 
insulin, 5.5 mg/ml transferrin, 5 ng/ml selenium, 0.5 mg/ml bovine 
serum albumin, 4.7 mg/ml linoleic acid) and 0.01 mM dexamethasone 
(Sigma Chemical, USA) [4] were added (serum free medium, SFM). 
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Luciferase assays 
The bioactivity of TGFβ3 was assessed using mink lung epithelial cells 
(tMLEC 32), transfected with a construct containing a luciferase gene 
from fireflies and inserted under the PAI-1 promoter, as previously 
described [7] (Fig. 1). Briefly, cells were seeded at the density of 4*104 
cells/well in white 96-well plates (Becton Dickinson, France). After the 
cells were allowed to attach for 4h, culture medium was replaced with 50 
μl of DMEM w/o phenol red (Gibco, UK), containing PSG and 1 mg/ml 
bovine serum albumin (Sigma Cell, USA). To determine the bioactivity 
of the stored sample relative to a freshly thawed standard, a dilution 
series was prepared to match the luciferase assay working range. For 
each condition, the dilution was prepared in quadruplicates. From this 
dilution plate, aliquots of 50 μl were transferred to the previously 
prepared assay plate and incubated for 14 h at 37°C/5% CO2. Next, 100 
μl of SteadyGloTM luciferase assay kit (Promega) were added to each 
well of the 96 well plate. The luciferase activity was measured at 20°C 
by a Topcount luminometer (Perkin Elmer, USA) with an integration 
time of 2s/well, and reported as counts per second.  
ELISA assays 
 Levels of TGFβ3 were also determined by a commercial ELISA 
kit (R&D Systems, Minneapolis, MN, USA), according to the 
manufacturer’s instructions. The samples stored at 37°C for up to 21 
days were assayed with reference to standard curves generated using 
human recombinant TGFβ3 (R&D Systems, Minneapolis, MN, USA). 
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Quantification of Relative Bioactivity 
Since the luciferase assay has relatively high inherent variability, 
the residual bioactivity of a stored TGFβ3 aliquot was derived by 
measuring the shift of its dilution curve from the standard curve. For this 
purpose, lines were fitted through three consecutive dose points of the 
dilution curves, using a parallel-line assay program (Stegmann 
Systemberatung, Germany) (Fig. 2A). The concentration range wherein 
the criteria for slope and parallelity were fulfilled was found to be 
between 0.08 to 0.625 ng/ml TGFβ3. Thus, experimental samples were 
diluted accordingly.  
Proliferation assays 
The biological effect of stored TGFβ3 was tested in chondrocyte 
proliferation assays, considering its marked effect when used in 
conjunction with Fibroblast Growth Factor (FGF)-2 [5]. Human articular 
chondrocytes were obtained after informed patient’s consent, following 
study protocol approval by the local ethical committee (Nr. 78/07), and 
cultured as previously published [5]. After the first passage in SCM, 
cells were seeded into tissue culture treated  96-well plates at a density 
of 2*103 cells/well, in 100 µl of medium. After 30 h, medium was 
supplemented with 5 ng/ml FGF-2 and an intended concentration of 1 
ng/ml TGFβ3 (for stored samples). After 4 days, cells were pulsed with 
3H-thymidine (1 mCi well, Amersham, UK) for 18 hours, harvested and 
the incorporated radioactivity was counted on a Top count reader  
(Perkin Elmer, USA). 
Statistical analyses 
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Differences between groups in luciferase, ELISA and 
proliferation assays were assessed by ANOVA with Tukey’s posthoc 
tests, and considered statistically significant if p < 0.05. 
 
Results and discussion 
Initially, SCM containing 10 ng/ml TGFβ3 was stored at 25°C or 
37°C for 1, 6 and 24 hours. The luciferase assay showed that at  either 
temperature the bioactivity of TGFβ3 was unaltered after 1 hour, but 
after 24 hours it was reduced to 89% at 25°C and down to 88% at 37°C. 
As there was no substantial difference between the two temperature 
conditions, further experiments were all performed at 37°C.  
In a second experimental setup, aliquots of SCM or SFM 
containing 10 ng/ml TGFβ3 were stored at 37°C for 1, 3, 7 and 21 days. 
The first significant reduction of the initial bioactivity was detected after 
3 days in SCM (p = 0.0011) or SFM (p = 0.0026). The residual 
bioactivity of TGFβ3 was significantly reduced over time (p = 2.7E-07), 
with a progressive loss down to 60% (p = 0.0150) in SCM and down to 
84% (p = 0.0003) in SFM after 1 week (Fig. 2B). Worthy of note, the 
residual bioactivity was not further decreased between 7 and 21 days, but 
remained at 63% in SCM and 73% in SFM.  
In order to confirm the loss of activity of TGFβ3, stored aliquots were 
also assessed for the whole amount of the factor using a structural 
ELISA assay, which does not reflect the bioactivity of the protein. 
Throughout the time of observation, the concentrations of TGFβ3 were 
similar in SCM and SFM, and after 21 days of storage remained at 
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102±8% and 105±3% of the initial levels, respectively in SCM and in 
SFM. The measured structural presence of TGFβ3 excluded typical 
explanations for the loss of protein bioactivity, related to aggregation [8] 
or adsorption to the surface of the storage vessel [9]. The trend of a 
slightly higher stability of TGFβ3 in SFM than in SCM (p = 8.4E-06 
using ANOVA on all time points, with culture medium as a factor) could 
be due to the presence in serum of α-Macroglobulin, which is known to 
bind to TGFβ and thereby form a latent complex [10].  
In order to clarify the practical relevance of the bioactivity loss measured 
by the luciferase assay, samples of freshly prepared or stored TGFβ3 
were assessed in a typical experimental system, namely for the 
proliferative effect on human articular chondrocytes in the presence of 
FGF-2 [5]. The reduction of the proliferative stimulus by serial dilutions 
of a freshly prepared sample starting from the concentration of 1 ng/ml 
first indicated the sensitivity of the assay, with a significant reduction 
(57±19%, p = 0.0043) in cell proliferation between 1 and 0.5 ng/ml (Fig. 
3A). Samples of TGFβ3 stored for different times were then diluted to 
the nominal concentration of 1 ng/ml and assessed for their proliferative 
effect. The slight reduction of the cell proliferation rate in the presence 
of stored TGFβ3 as compared to the freshly prepared standard was 
consistent with the functional loss of 15-40% measured by the luciferase 
assay (Fig. 2B) and the dose-response curve in TGFβ3-induced 
proliferation (Fig. 3A). Interestingly, however, such reduction was not 
statistically significant at any investigated storage time, indicating a 
negligible relevance of the TGFβ3 bioactivity loss in our experimental 
system. 
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Conclusions 
This study demonstrates a significant loss of TGFβ3 bioactivity 
during storage under typical conditions, which could not have been 
predicted using a conventional ELISA method. The fact that this loss did 
not significantly affect the biological readout in our investigated 
experimental setup (i.e., chondrocyte proliferation rate) supports the 
possibility of having TGFβ3 pre-supplemented in the proliferation 
medium for bioreactor-based chondrocyte expansion [11]. 
With the ultimate goal of defining suitable storage conditions 
of culture media in automated bioreactors for cell culture, the proposed 
approach and methods should be extended to assessing the stability of 
other possibly labile medium supplements.  
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Figure legends 
 
Figure 1 
Luciferase Assay Principle: Binding of TGFβ3 to its receptor in mink 
lung epithelial cells transfected with a construct containing luciferase 
(tMLEC) induces a dose dependent increase of luciferase expression 
through the PAI-1 promoter. After adding the reagent Beetle Luciferin to 
the cell lysate, the emitted luminescence is acquired by use of a 
luminometer. 
 
Figure 2 
(A) Typical luminescence curves for the luciferase assay in the presence 
of different concentrations of TGFβ3. The residual bioactivity of stored 
TGFβ3 as compared to the freshly thawed standard was calculated from 
the shift between the parallel lines fitted through the two dilution curves. 
Error bars indicate standard deviations (n = 4 independent data sets per 
experimental condition). (B) Bioactivity stability of TGFβ3 in serum 
containing medium or serum free medium. Bars indicate the measured 
bioactivity relative to a freshly thawed standard. Asterisks indicate a 
statistically significant difference from the corresponding condition (i.e., 
using the same medium) at day 1. Error bars indicate a confidence 
interval of 95% (n = 3 independent data sets per experimental condition). 
 
Figure 3 
Proliferation of human articular chondrocytes in the presence of TGFβ3 
at different concentrations or storage times, assessed by [3H]-Thymidine 
 12 
incorporation and expressed as counts per minute (CPM). (A) Dilution 
series starting from 1 ng/ml TGFβ3 of a freshly prepared standard. The 
overhead bracket with asterisk indicates a statistically significant 
difference between groups (n = 4 independent data sets per experimental 
condition). (B) Proliferative effect of TGFβ3 following storage in SCM 
at 37°C for up to 21 days. Stored samples of 10 ng/ml TGFβ3 were 
diluted in fresh SCM to result in an intended final concentration of 1 
ng/ml TGFβ3, a concentration typically applied for chondrocyte 
proliferation. Dashed lines indicate the expected range of cell 
proliferation for a freshly prepared standard, based on results presented 
in part (A). All values are presented as mean ± standard deviation (n = 4 
independent data sets per experimental condition). 
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